IN Brief:
- Danone is selling its 22.7% stake in US kefir producer Lifeway Foods.
- The secondary offering covers 3.45 million shares priced at $19.50 each.
- The move ends a long-running relationship marked by takeover attempts, legal tension, and fermented dairy growth.
Danone is selling its full stake in US kefir producer Lifeway Foods, closing a 27-year shareholding in one of the most prominent fermented dairy businesses in the American market.
The French dairy group held approximately 22.7% of Lifeway. The disposal is being made through a secondary underwritten public offering of 3.45 million shares priced at $19.50 each, with gross proceeds of around $67m. Lifeway will not receive proceeds from the shares sold by Danone, although it has agreed to repurchase around $5m of stock at the same offering price, subject to completion of the wider transaction.
The sale follows a period of tension between the two companies. Danone made acquisition approaches for Lifeway in 2024, including proposals valuing the business at $25 and then $27 per share. Lifeway rejected the offers, arguing that they undervalued the company. Relations then deteriorated around governance and legal disputes before later discussions failed to produce a transaction.
Lifeway has remained one of the defining names in US kefir. The company’s cultured dairy products sit at the intersection of traditional fermented milk, functional nutrition, gut-health positioning, and high-protein chilled dairy. Danone is stepping away from direct exposure to a growing specialist player, while the wider category continues to attract attention from processors seeking higher-value dairy formats.
For dairy processors, the move highlights the difference between category growth and ownership fit. Fermented dairy continues to perform well in markets where protein, digestion, immunity, and convenience are driving chilled innovation. Growth alone, however, does not guarantee that minority stakes, acquisition attempts, and governance structures remain workable. Global groups are becoming more selective about where they want control, partnership, or exposure without ownership complexity.
The sale also comes as dairy manufacturers reassess how to capture more value from milk streams, cultures, and processing assets. Rodda’s £6m investment in dedicated cottage cheese capacity shows the same pressure in the UK, where processors are moving into higher-protein chilled formats while improving utilisation of milk already entering their sites. Lifeway sits in a different market, but the category logic is similar: dairy plants are being pushed to make milk work harder.
Fermented dairy creates particular manufacturing demands. Cultures, incubation, cooling, viscosity control, filling hygiene, shelf-life validation, and cold-chain discipline all shape the finished product. Brand strength may lead the commercial conversation, but process control determines whether fermented products can scale without quality drift. Kefir, yoghurt drinks, cultured smoothies, cottage cheese, and high-protein chilled products all depend on repeatable biological processes that are sensitive to time, temperature, formulation, and sanitation.
The Lifeway sale may also sharpen attention on the fragmented nature of functional dairy in the US. Large groups want exposure to health-led categories, yet founder-led or specialist businesses can be difficult to integrate where identity, culture, and growth expectations are central to the brand. Minority investment can provide access, but it can also leave strategic decisions unresolved when performance improves and valuation expectations diverge.
Danone’s exit removes one overhang from Lifeway’s shareholder structure and gives the kefir producer a clearer path as an independent listed business. It also gives Danone a cleaner capital position after a contested acquisition chapter. Fermented dairy remains attractive, but control, scale, processing discipline, and manufacturing focus will decide which companies convert that attraction into durable growth.
